{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:34:21Z","timestamp":1760524461208,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006742","name":"Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio","doi-asserted-by":"publisher","award":["SGA4Cancer-GI2-CESPU-2022","upPTXovcar-GI2-CESPU-2022","Flav4Tumor-GI2-CESPU-2022"],"award-info":[{"award-number":["SGA4Cancer-GI2-CESPU-2022","upPTXovcar-GI2-CESPU-2022","Flav4Tumor-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Owing to the exceptional complexity of the development and progression of cancer, diverse cancer types are alarmingly increasing worldwide [...]<\/jats:p>","DOI":"10.3390\/pharmaceutics15020605","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T04:32:58Z","timestamp":1676262778000},"page":"605","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Anticancer Strategies II"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5779","authenticated-orcid":false,"given":"Hassan","family":"Bousbaa","sequence":"first","affiliation":[{"name":"UNIPRO-Oral Pathology and Rehabilitation Research Unit, Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal"},{"name":"Centro Interdisciplinar de Investiga\u00e7\u00e3o Marinha e Ambiental (CIIMAR), Universidade do Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Av. General Norton de Matos s\/n, 4450-208 Matosinhos, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bousbaa, H. (2021). Novel Anticancer Strategies. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020275"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cao, Y., Chen, C., Tao, Y., Lin, W., and Wang, P. (2021). Immunotherapy for Triple-Negative Breast Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122003"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zha, H., Xu, Z., Xu, X., Lu, X., Shi, P., Xiao, Y., Tsai, H.-I., Su, D., Cheng, F., and Cheng, X. (2022). PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061263"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pao, S.-C., Chu, M.-T., and Hung, S.-I. (2022). Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040867"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kashyap, D., Garg, V.K., Sandberg, E.N., Goel, N., and Bishayee, A. (2021). Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040569"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Novais, P., Silva, P.M.A., Amorim, I., and Bousbaa, H. (2021). Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071011"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pinto, B., Novais, P., Henriques, A.C., Carvalho-Tavares, J., Silva, P.M.A., and Bousbaa, H. (2022). Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061209"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Silva, P.M.A., and Bousbaa, H. (2022). BUB3, beyond the Simple Role of Partner. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051084"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Teixeira, C.S.S., and Sousa, S.F. (2021). Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010010"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bartolucci, D., Pession, A., Hrelia, P., and Tonelli, R. (2022). Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071453"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Soond, S.M., Savvateeva, L.V., Makarov, V.A., Gorokhovets, N.V., Townsend, P.A., and Zamyatnin, A.A. (2021). Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030339"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Leis-Filho, A.F., de Faria Lainetti, P., Emiko Kobayashi, P., Fonseca-Alves, C.E., and Laufer-Amorim, R. (2021). Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060897"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Quiroz-Reyes, A.G., Delgado-Gonzalez, P., Islas, J.F., Gallegos, J.L.D., Mart\u00ednez Garza, J.H., and Garza-Trevi\u00f1o, E.N. (2021). Behind the Adaptive and Resistance Mechanisms of Cancer Stem Cells to TRAIL. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071062"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Feliz Morel, \u00c1.J., Hasanovic, A., Morin, A., Prunier, C., Magnone, V., Lebrigand, K., Aouad, A., Cogoluegnes, S., Favier, J., and Pasquier, C. (2022). Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050988"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Fu, Y., Ci, H., Du, W., Dong, Q., and Jia, H. (2022). CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020275"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bukhari, S.I., Imam, S.S., Ahmad, M.Z., Vuddanda, P.R., Alshehri, S., Mahdi, W.A., and Ahmad, J. (2021). Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060840"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Javed, S., Alshehri, S., Shoaib, A., Ahsan, W., Sultan, M.H., Alqahtani, S.S., Kazi, M., and Shakeel, F. (2021). Chronicles of Nanoerythrosomes: An Erythrocyte-Based Biomimetic Smart Drug Delivery System as a Therapeutic and Diagnostic Tool in Cancer Therapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030368"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Montaseri, H., Kruger, C.A., and Abrahamse, H. (2021). Inorganic Nanoparticles Applied for Active Targeted Photodynamic Therapy of Breast Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030296"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stiltner, J., McCandless, K., and Zahid, M. (2021). Cell-Penetrating Peptides: Applications in Tumor Diagnosis and Therapeutics. Pharmaceutics, 13.","DOI":"10.20944\/preprints202105.0513.v1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Md, S., Alhakamy, N.A., Karim, S., Gabr, G.A., Iqubal, M.K., and Murshid, S.S.A. (2021). Signaling Pathway Inhibitors, MiRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122120"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gabriele, V.R., Mazhabi, R.M., Alexander, N., Mukherjee, P., Seyfried, T.N., Nwaji, N., Akinoglu, E.M., Mackiewicz, A., Zhou, G., and Giersig, M. (2021). Light- and Melanin Nanoparticle-Induced Cytotoxicity in Metastatic Cancer Cells. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13070965"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Singh, B., Shukla, N., Kim, J., Kim, K., and Park, M.-H. (2021). Stimuli-Responsive Nanofibers Containing Gold Nanorods for On-Demand Drug Delivery Platforms. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081319"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Puiu, R.A., Balaure, P.C., Constantinescu, E., Grumezescu, A.M., Andronescu, E., Oprea, O.-C., Vasile, B.S., Grumezescu, V., Negut, I., and Nica, I.C. (2021). Anti-Cancer Nanopowders and MAPLE-Fabricated Thin Films Based on SPIONs Surface Modified with Paclitaxel Loaded \u03b2-Cyclodextrin. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091356"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nistorescu, S., Udrea, A.-M., Badea, M.A., Lungu, I., Boni, M., Tozar, T., Dumitrache, F., Maraloiu, V.-A., Popescu, R.G., and Fleaca, C. (2021). Low Blue Dose Photodynamic Therapy with Porphyrin-Iron Oxide Nanoparticles Complexes: In Vitro Study on Human Melanoma Cells. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122130"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"van Zundert, I., Bravo, M., Deschaume, O., Cybulski, P., Bartic, C., Hofkens, J., Uji-i, H., Fortuni, B., and Rocha, S. (2021). Versatile and Robust Method for Antibody Conjugation to Nanoparticles with High Targeting Efficiency. Pharmaceutics, 13.","DOI":"10.1101\/2021.09.29.462399"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Studenovsk\u00fd, M., Rumlerov\u00e1, A., Kov\u00e1\u0159ov\u00e1, J., Dvo\u0159\u00e1kov\u00e1, B., Siv\u00e1k, L., Kostka, L., Berd\u00e1r, D., Etrych, T., and Kov\u00e1\u0159, M. (2022). HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061201"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kondo, N., Hirano, F., and Temma, T. (2022). Evaluation of 3-Borono-l-Phenylalanine as a Water-Soluble Boron Neutron Capture Therapy Agent. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051106"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Jurado, E., Cimas, F.J., Castro-Osma, J.A., Juan, A., Lara-S\u00e1nchez, A., Rodr\u00edguez-Di\u00e9guez, A., Shafir, A., Oca\u00f1a, A., and Alonso-Moreno, C. (2021). Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101559"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Costa, B., and Vale, N. (2021). A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060815"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yamakawa, H., Setoguchi, S., Goto, S., Watase, D., Terada, K., Nagata-Akaho, N., Toki, E., Koga, M., Matsunaga, K., and Karube, Y. (2021). Growth Inhibitory Effects of Ester Derivatives of Menahydroquinone-4, the Reduced Form of Vitamin K2(20), on All-Trans Retinoic Acid-Resistant HL60 Cell Line. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050758"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kej\u00edk, Z., Kapl\u00e1nek, R., Dytrych, P., Masa\u0159\u00edk, M., Vesel\u00e1, K., Abramenko, N., Hoskovec, D., Va\u0161\u00e1kov\u00e1, M., Kr\u00e1lov\u00e1, J., and Mart\u00e1sek, P. (2021). Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111879"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Quarta, A., Gallo, N., Vergara, D., Salvatore, L., Nobile, C., Ragusa, A., and Gaballo, A. (2021). Investigation on the Composition of Agarose\u2013Collagen I Blended Hydrogels as Matrices for the Growth of Spheroids from Breast Cancer Cell Lines. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13070963"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/605\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:30:38Z","timestamp":1760121038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmaceutics15020605"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15020605","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}